Drug intelligence / Profile preview

H2007

Development stage: Preclinical
Lead developer: Hotgen Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

H2007 is a therapeutic monoclonal antibody developed by Beijing Hotgen Biotech for the treatment of various cancers. It is designed to modulate the immune system's response to tumors, with a mechanism of action associated with the PD-1/PD-L1 checkpoint pathway. According to pipeline information, H2007 exhibits anti-tumor effects similar to established PD-1/PD-L1 inhibitors and has demonstrated the potential to enhance therapeutic efficacy when used in combination with other checkpoint inhibitors. It is currently being explored as an anti-tumor therapy to improve outcomes in patients with solid tumors.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on H2007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H2007.

Explore the full profile